Plain-English translation of NCT06449833 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether henagliflozein, a new diabetes medication, can help reduce fat that builds up in the liver. You have both type 2 diabetes and nonalcoholic fatty liver disease — a condition where too much fat accumulates in your liver without being caused by alcohol. The study will compare the new medication against a standard diabetes drug to see which one works better at reducing liver fat over 24 weeks.
Many people with type 2 diabetes also develop fatty liver disease, which can lead to serious liver damage over time. This medication may offer a better way to control blood sugar while also helping to reduce the dangerous fat buildup in the liver.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either the new medication henagliflozein plus metformin, or a standard diabetes medication (linagliptin) plus metformin for 24 weeks. You'll visit the clinic at weeks 8, 16, and 24 for check-ups and testing. Throughout the study, nutritionists will provide guidance on diet and exercise to support your health. At the end, doctors will compare how much liver fat decreased in each group.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China